Johnson & Johnson Told to Pay $8 Billion in Damages

In August 2017, we looked at a case whereby Johnson & Johnson, the global pharmaceutical company, were ordered to pay more than $400 million in damages. However, this month a Jury in Philadelphia decided that the company would face a much higher financial penalty on account of its development and marketing of an anti-psychotic drug that has been linked to the development of breast tissue in men. In this post we will look at this award, what it means for J&J, and what happens next.

The case has been brought by Nicholas Murray of Maryland, who has claimed that he developed female breast tissue after taking the drug Risperdal when he was younger. It has been reported that the drug has been linked to the abnormal growth of breast tissue in boys. Risperdal is used to treat a number of mental/mood disorders, including schizophrenia, bipolar disorder, and some variants of autistic disorder. The US Food and Drug Administration approved the drug for use in 1993 for these conditions. When assessing online medical websites, the associated side-effects seem to be common for this type of drug (dizziness, difficulty swallowing, mood changes etc.), but now this new link has fundamentally changed the conversation surrounding this drug.

In just one of thousands of cases pending on this subject, Murray had claimed that J&J failed to warn of the risk of ‘gynecomastia’, and that the company had marketed the drug for the usage of children, in appropriately. In 2015 a jury awarded Murray $1.75 million for not warning against the risk of gynecomastia, but this was reduced to $680,000 on appeal. Murray’s lawyers stated that the ‘conduct that the jury saw in the courtroom, was clear and convincing that J&J disregarded the safety of the most vulnerable of children’ and that J&J is a company ‘that has lost its way’. Whilst J&J have responded by saying that the award is ‘grossly disproportionate with this initial compensatory award in this case’ and that it will be appealing, the horizon looks troubling for the corporate giant.

This month the company reported third-quarter earnings and revenue figures that beat expectations (revenue was around $20 billion), the potential for losses relating to legal issues is mounting every day. This current case is potentially going to open the floodgates, especially as a court recently allowed for a mass tortious litigation to take place. Yet, cases relating to sale of this particular drug are not the company’s only problem. They are also currently embroiled in cases surrounding the cancerous effects of baby powder, their development and distribution of opioid-based products, and also artificial hips – in May the company agreed to settle for more than $1 billion for the manufacture and sale of defective metal-on-metal hip replacements. Add to this the liability the company is facing regarding the development of defective vaginal mesh products, it becomes clear the company is facing serious legal difficulties in spite of its good financial performance. It has been suggested in the media that settling these cases will cost the company near $20 billion, but that is certainly not set in stone. Depending upon the example that the judiciary may want to set, it could be much higher indeed.

The question then becomes what this all means for J&J moving forward. Its shares are down in response to the potential for liability costs, but they will probably rebound. However, it is the company’s business practice that is being called into question, with it being commented that the company used to be known for its gold-standard ethical approach and, now, that is evaporating. Yet, it may just be the case that the environment around J&J is changing rapidly, and they are being caught out. 30/40/50 years ago, the ingredients and effects of their baby powder were not high on the agenda, but in the current climate that focuses on health, wellbeing, and sustainability, they are. The effect of the opioid crisis and the new demographic of its victims has shone a light on the selling practices of these massive firms, and J&J has been found to have come up short. Perhaps the important question is what J&J will do now moving forward. If the financial penalty is large enough, the move to reacquaint themselves with those gold-standard ethical principles will be more attractive. However, if they can ride this wave, or ‘bronco’, and come out of it intact, then there is less of an incentive to change. The collective financial penalty has to be so large so as to inspire change because that is the only form of punishment that is allowed within the current system – J&J executives will not be personally punished for the drop in standards, only financially punished by proxy. The future for J&J, and for their customers, hinges on how they react to this current crisis facing them as a company.


Keywords – Johnson & Johnson, Pharmaceuticals, business, law, @finregmatters

Comments

Post a Comment

Popular posts from this blog

Lloyds Bank and the PPI Scandal: The Premature ‘Out of the Woods’ Rhetoric

Image
Today’s very short post focuses upon the news that the Financial Conduct Authority (FCA) has recently extended the deadline to claim compensation for mis-sold ‘Payment Protection Insurance’ (PPI). Whilst a lot of financial institutions will have to prepare to offset the extended deadline, it is Lloyds that has grabbed the business headlines by apportioning an extra £350 million to offset any further claims that may be made of it – however, this comes only a week or two after the Bank posted its best performance figures in over a decade, as was previously discussed in Financial Regulation Matters . This post will therefore argue that the rhetoric being advanced recently regarding Lloyds – rhetoric like Lloyds represents ‘ a modern day success story ’ is wide of the mark and creates a false sense of security that we simply cannot afford to believe in. The ‘ robust recovery ’ was heralded far and wide upon the publication of Lloyds Bank’s financial performance for the previous fi
Read more

The Analytical Credit Rating Agency: A New Entrant That Will Further Enhance Russia’s Isolation

Image
This short post is based upon a forthcoming article by this author that examines the viability of the latest entrant into the credit rating arena, the Analytical Credit Rating Agency (ACRA). The article, which is due to be published in the European Company Law Journal (and is available here in a pre-published version), looks at the chances of the ACRA succeeding when viewed within the parameters of perception , an aspect that underpins the credit rating sector. For this post, the focus will be upon introducing the ACRA, and then on examining the effect it may have upon the wider political issues affecting the Russian Federation. The Analytical Credit Rating Agency was established in November 2015 and comprises of 27 major Russian companies and financial institutions that serve as its shareholders. The agency, which became the first rating agency to receive accreditation from the Russian Central Bank under the new N 222-FZ Law which was designed to protect investors, has a re
Read more

The Case of Purdue Pharma, the Sackler Family, and the Opioid Crisis

Image
In the first of two short posts today, we will look at the case of the billionaire Sackler Family and their remarkable effect upon American society. The family, who own Purdue Pharma amongst a list of other ventures, have this week seen a massive legal action taken against them by the State of New York who argue that the company is ‘ responsible for the opioid epidemic ’ sweeping through the United States. The attorney-general for New York has called the lawsuit the ‘ nation’s most extensive ’ with respect to the pharmaceutical industry and comes right on the heels of a $270 million suit that was settled in the State of Oklahoma on exactly the same grounds. Whilst the company and the billionaire family who own it did not admit guilt (settling parties rarely do, hence why they settle outside of court) it has potentially opened the trapdoors for litigation. It comes as no surprise then that the company is reportedly considering bankruptcy proceedings in the face of such an onsl
Read more